SeaBeLife
Unlock your access to Venture Investment Opportunities with OurCrowd
Website
seabelife.comOverview: SeaBeLife
SeaBeLife is a biotechnology company based in Bretagne, specializing in developing innovative therapeutic solutions to protect cells and organs from regulated necrosis, also known as regulated cell death.
Their patented technology aims to block programmed cell death, particularly targeting major organs such as the liver, kidneys, heart, and brain.
SeaBeLife focuses on developing candidate molecules that can simultaneously block two forms of regulated cell death to protect organs under attack from diseases.
The company's primary objective is to address acute and orphan diseases with unique or brief treatment options, with a focus on severe hepatitis as their gateway indication.
SeaBeLife aims to expand their indications to include treatments for acute renal failure, myocardial infarctions, strokes, dry age-related macular degeneration (ADM), and neurodegenerative diseases.
Their therapeutic approach includes inhibiting regulated cell death to protect at-risk cells and combat organ injuries.
SeaBeLife's products target specific conditions such as Acute Hepatic Insufficiency (AHI) and Fulminant Hepatic Failure (FHF), age-related Macular Degeneration (AMD), Parkinson's disease, acute renal failure, myocardial infarctions, strokes, and other neurodegenerative diseases.
By blocking regulated cell necrosis, the company aims to prevent cell death and protect vital organs from irreversible damage.
The unique mechanism of action of SeaBeLife's drugs involves blocking both necroptosis and ferroptosis, two forms of regulated necrosis that communicate and cause cell death.
By simultaneously targeting these processes, SeaBeLife's molecules offer a novel approach to protecting cells and tissues from inflammation and oxidative stress associated with various diseases.
SeaBeLife at a Glance
- Developing innovative therapeutic solutions to protect organs from regulated necrosis
- Focusing on acute and orphan diseases with unique treatment options
- Targeting severe hepatitis as a gateway indication and expanding to other conditions
- Novel mechanism of action targeting necroptosis and ferroptosis simultaneously
SeaBeLife News
Sentiment Score 96
(Out of 100 max value)
(Out of 100 max value)
- News Articles 9
- Positive News Articles 9
- Neutral News Articles 0
- Negative News Articles 0
SeaBeLife receives Orphan Drug Designation from EMA for acute liver failure treatmentPublisher European Pharmaceutical Manufacturer
- News Summary
- Expand SeaBeLife has announced the granting of an Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its drug candidate SBL01 . Acute liver failure (ALF) occurs when the liver suddenly loses its ability to function in a person without a pre-existing liver disorder . In the EU, the population of patients with ALF is estimated to be between 1.3 and 3.1 in 10,000 . This meets the EMAs orphan designation threshold, which is targeted at conditions
- Key People Mentioned
- Morgane Rousselot
SeaBeLife awarded over €1.5 million in i-Nov innovation competitionPublisher MENAFN.COM
- News Summary
- SeaBeLife, a biotechnology company developing drug candidates to block cellular necrosis, today announces the award of more than 1.5M ($1.6M) in financing for its SeaBeEYE project at the i-Nov 2024 innovation competition . It will be used to develop new therapeutic approach for geographic atrophy advanced form of dry AMD Roscoff, France, April 22, 2024 . In this, its 11th financing round, from 149 applications, it awarded funds to 42 projects .
- Key People Mentioned
- Roscoff | Morgane Rousselot
- Key Locations Mentioned
- Europe
Biotech SeaBeLife awarded €1.5M to combat visual degenerationPublisher Tech.eu
- News Summary
- SeaBeLife has been awarded 1.5M for its SeaBeEYE project at the i-Nov 2024 innovation competition . The competition aims to support some of the highly innovative projects developed by French businesses . Geographic atrophy is a serious ophthalmological disease that affects over five million patients worldwide .
- Key People Mentioned
- Morgane Rousselot
Seabelife SAS to develop next-gen dry AMD drugPublisher European Biotechnology News
- News Summary
- SeaBeLife SAS has bagged a 1.5m fund within the i-Nov 2024 innovation competition . The drugmaker will use the fresh proceeds to advance a topical formulation of a small molecule drug to treatgeographic atrophy . In vitro, SBL03 blocked two forms of regulated necrosis that lead to photoreceptor cell death and vision loss .
- Key People Mentioned
- Marie-Therese Dimanche-Boitrel | Claire Delehouz | Stephane Bach | Morgane Rousselot
Biotech SeaBeLife awarded €1.5M to combat visual degenerationPublisher Tech.eu
- News Summary
- SeaBeLife has been awarded 1.5M for its SeaBeEYE project at the i-Nov 2024 innovation competition . The competition aims to support some of the highly innovative projects developed by French businesses . Geographic atrophy is a serious ophthalmological disease that affects over five million patients worldwide .
- Key People Mentioned
- Morgane Rousselot
Access exclusive deals
Join for free and be notified of future investment opportunities
Some of the content on this page is AI-generated based on publicly available third-party sources. OurCrowd does not take responsibility for the accuracy of this information. Please verify any details independently before making any decisions based on this content.